What’s Hot with VC Investors University of Pennsylvania Commercialization Series September 18, 2019 Barbara S. Schilberg, CEO
1
www.bioadvance.com
Whats Hot with VC Investors University of Pennsylvania - - PowerPoint PPT Presentation
Whats Hot with VC Investors University of Pennsylvania Commercialization Series September 18, 2019 Barbara S. Schilberg, CEO www.bioadvance.com 1 Topics today BioAdvance update Where is VC money going today? Regional
1
www.bioadvance.com
2
3
4
5
products approved by the FDA (plus 23 others marketed)
invested in
companies, developing
in additional dollars (a 1:61 leverage ratio) and
products, leveraging
6
New formulation of rapamycin for pachyonychia congenita - $3M Series A-1; $5M Series B Anti-endothelin B to use with checkpoint inhibitors to activate T-cells - $6.5M Series A Software to improve feeding management in the NICU - $1.1M Seed; $1.75M Series A Medical food for cystic fibrosis - $4.5M Series A Gene therapy for rare monogenic heart disease - $11M Series A
MNI Renovacor
7
8
Source:
9
10
11
Immuno/oncology ($4.4B) Rare diseases ($2B) Gene and cell therapies Platform companies
Infectious disease Diagnostics
Half of VC funding for therapeutics went to pre-clinical companies
Source: BIO 2019 Emerging Company Report
12
Source: Pitchbook
13
Value 1 (bar graph): Total Capital Invested Value 2 (line graph): Deal
$109.93M $80.45M $43.71M $44.54M $101.40M $74.59M $355.92M $64.82M $546.73M $114.08M $417.84M 17 10 8 14 20 18 22 16 21 15 22 $0.00M $100.00M $200.00M $300.00M $400.00M $500.00M $600.00M 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 Source: PitchBook Data, Inc. Capital Invested Deal Count
14
15
State 2017 MA 183 NY 264 NJ 19 PA 44 DE 11 MD 19 2018 137 322 20 34 8 29
Number of Active Investors by HQ State (All Sectors)
16
17
18
19
JPMorgan (SFO) RESI (Boston and NYC) BIO Life Sciences Summit (NYC) HIMSS and SXSW (digital health)
Pitchbook News Big4Bio Fierce daily newsletters (Biotech; HealthIT, others) Faster Cures BIO Smart Brief
20
21
22
23
Product sales Acquisition by another company (exit) Initial public offering
Rule of thumb--$1 of investor money should create $3-$10
24
Skills that are relevant to the near-term plan A history of successful execution (“been there, done that”) The ability to operate in a small company environment E.Q.
Hire your family Think that because you are a successful academic you can be a CEO Go it alone
25
26
FAQs Team bios Portfolio company list
Barbara Schilberg (bschilberg@bioadvance.com)
27